Współczesna Onkologia, Год журнала: 2023, Номер 27(4), С. 277 - 283
Опубликована: Янв. 1, 2023
AMA Gibek K. Side effects of treatment with tyrosine kinase inhibitors in patients chronic myeloid leukaemia and the occurrence depressive symptoms. Contemporary Oncology/Współczesna Onkologia. 2024. doi:10.5114/wo.2023.135362. APA Gibek, (2024). https://doi.org/10.5114/wo.2023.135362 Chicago Katarzyna. "Side symptoms". Harvard MLA symptoms." Onkologia, Vancouver
Язык: Английский
Nature Medicine, Год журнала: 2024, Номер 30(1), С. 51 - 60
Опубликована: Янв. 1, 2024
Язык: Английский
Процитировано
22
Gut, Год журнала: 2023, Номер 73(2), С. 311 - 324
Опубликована: Сен. 14, 2023
Background This study investigates sex disparities in clinical outcomes and tumour immune profiles patients with pancreatic ductal adenocarcinoma (PDAC) who underwent upfront resection or preceded by gemcitabine-based neoadjuvant chemoradiotherapy (nCRT). Methods Patients originated from the PREOPANC randomised controlled trial. Upfront surgery was performed 82 patients, 66 received nCRT before resection. The impact of on overall survival (OS) investigated using Cox proportional hazards models. immunological landscape within microenvironment (TME) mapped transcriptomic spatial proteomic profiling. Results 5-year OS rate differed between sexes following nCRT, 43% for women compared 22% men. In multivariate analysis, female a favourable independent prognostic factor only group (HR 0.19; 95% CI 0.07 to 0.52). Multivariate heterogeneous treatment effects analysis revealed significant interaction treatment, implying increased efficacy among resected PDAC. TME contained fewer protumoural CD163+MRC1+M2 macrophages than that men after as indicated validated Conclusion PDAC tumours are more sensitive resulting longer may be due enhanced immunity impeding infiltration protumoral M2 into TME. Our findings highlight importance considering mitigating immunosuppressive macrophage polarisation personalised treatment.
Язык: Английский
Процитировано
22
Biology of Sex Differences, Год журнала: 2024, Номер 15(1)
Опубликована: Авг. 6, 2024
Lung adenocarcinoma (LUAD) has been observed to have significant sex differences in incidence, prognosis, and response therapy. However, the molecular mechanisms responsible for these disparities not investigated extensively.
Язык: Английский
Процитировано
9
Frontiers in Medical Technology, Год журнала: 2024, Номер 6
Опубликована: Фев. 1, 2024
Sex hormones play a pivotal role in modulating various physiological processes, with emerging evidence underscoring their influence on cancer progression and treatment outcomes. This review delves into the intricate relationship between sex cancer, elucidating underlying biological mechanisms clinical implications. We explore multifaceted roles of estrogen, androgens, progesterone, highlighting respective specific cancers such as breast, ovarian, endometrial, prostate. Special attention is given to estrogen receptor-positive (ER+) receptor-negative (ER−) tumors, androgen receptor signaling, dual progesterone both promoting inhibiting progression. Clinical observations reveal varied responses contingent upon hormonal levels, certain therapies like tamoxifen, aromatase inhibitors, anti-androgens demonstrating notable success. However, disparities outcomes males females hormone-sensitive necessitate further exploration. Therapeutically, utilization hormone replacement therapy (HRT) during treatments presents potential risks benefits. The promise personalized therapies, tailored an individual’s profile, offers novel approach optimizing therapeutic Concurrently, burgeoning exploration new drugs interventions targeting pathways heralds future more effective precise for cancers. underscores pressing need deeper understanding ensuing implications innovations.
Язык: Английский
Процитировано
4
Cancer Epidemiology, Год журнала: 2024, Номер 92, С. 102565 - 102565
Опубликована: Апрель 4, 2024
Язык: Английский
Процитировано
4
European Journal of Cancer, Год журнала: 2024, Номер 206, С. 114117 - 114117
Опубликована: Май 14, 2024
Язык: Английский
Процитировано
3
Clinical & Translational Oncology, Год журнала: 2025, Номер unknown
Опубликована: Янв. 17, 2025
Abstract Males have a higher incidence and mortality rate from colorectal cancer (CRC) compared with females. This review examines the reasons for these differences, including risk factors, screening participation, interpretation of tests, presentation tumour types, pathophysiology (particularly impact sex hormones on tumour-related gene expression, microsatellite instability, micro-RNA microenvironment), efficacy toxicity treatment. Sex differences in body composition are responsible some sexual dimorphism CRC outcomes, particularly pathophysiology, presentation, pharmacokinetics cytotoxic therapies, treatment outcomes. However, gender also play role, affecting access to or participation treatment, patients’ experience (e.g. adverse events sequelae). issues warrant further investigation optimise outcomes patients.
Язык: Английский
Процитировано
0
Langenbeck s Archives of Surgery, Год журнала: 2025, Номер 410(1)
Опубликована: Фев. 7, 2025
Combination of gemcitabine and cisplatin (GemCis) is the current first-line treatment for unresectable biliary tract cancer (UR-BTC), but it confers a median overall survival (OS) less than one year. This study aimed to evaluate benefit conversion surgery initially UR-BTC. Eligible studies published between January 2000 May 2024 were identified via an electronic search PubMed Web Science databases. The primary endpoint was OS. Included in this 96 observational involving 466 patients with 231 cases (49.6%) intrahepatic cholangiocarcinoma, 131 (28.1%) extrahepatic 104 (22.3%) gallbladder cancer. 90-day mortality rate 4.3%, duration 36.8 (17.9-57.6) months, 1-, 3- 5-year OS 86% (74-95.9%), 59.9% (32.3-78.7%), 41.1% (24-58.5%) respectively. Meta-analysis showed that who underwent significantly higher those received non-surgical (hazard ratio [HR] 0.39, P < 0.001) comparable up-front resectable (HR 1.02, = 0.43). Pooled analysis 149 individual participant data male gender 20.649, 0.014) lymph node metastasis 14.671, 0.005) independently associated reduced Conversion justified UR-BTC favorable long-term survival, may prove be promising option multimodality
Язык: Английский
Процитировано
0
Cancers, Год журнала: 2025, Номер 17(7), С. 1054 - 1054
Опубликована: Март 21, 2025
Significant sex-based differences exist in the immune system and antitumor responses, potentially leading to variations both efficacy toxicity of anticancer immunotherapies. Women generally mount stronger innate adaptive responses than men, which can result more severe immune-related adverse events (irAEs) during treatments with checkpoint inhibitors (ICIs). However, importance sex dimorphism safety cancer immunotherapy remains underexplored clinical oncology, despite its profound implications for treatment outcomes. Our review highlights critical influence biological on pharmacokinetics, pharmacodynamics, shaping ICI prevalence, type, severity irAEs. Integrating as a variable trial design is essential personalizing therapeutic strategies, bridging existing knowledge gaps, enhancing survival rates quality life patients across genders.
Язык: Английский
Процитировано
0
The Oncologist, Год журнала: 2025, Номер 30(3)
Опубликована: Март 1, 2025
High-grade chemotherapy-induced peripheral neuropathy (CIPN) represents a dreaded toxicity of cancer treatments. In some cases, it may limit activities daily living and become permanent. Because many prior studies CIPN were conducted in breast populations, less is known about men. We therefore determined the incidence correlates high-grade large cohort patients with lung cancer. collected data from ECOG-ACRIN E1594 (comparison 4 chemotherapy regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, carboplatin-paclitaxel) E4599 (carboplatin-paclitaxel ± concurrent maintenance bevacizumab) clinical trials. identified cases grade ≥3 CIPN. Multivariable logistic regression modeling was performed to estimate adjusted odds ratios according patient characteristics. Among 1,998 included study, 167 (8%) developed Grade associated higher body mass index (BMI) (P = .01), sex (7% for men vs 10% women; P .005), age (11% ≥65 years 7% <65 years; < .001), regimen greater number treatment cycles .001). multivariate model, regimens featuring doses paclitaxel or cisplatin, cycles, female sex, age, BMI remained independently type exposure, elevated BMI. Given ongoing use cytotoxic agents established new (eg, antibody-drug conjugates) regimens, these findings have implications monitoring selection.
Язык: Английский
Процитировано
0